Skip to main content
SpringerLink
Log in

Caspofungin

L 743872, MK 0991, MK 991

  • Section 2: Antifungal Agent
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stone JA, Holland SD, Ju WD, et al. Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man [abstract 83]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego. Presse Med 1998 Dec; 27 (5 Suppl.): 83

    Google Scholar 

  2. Sable CA, Villanueva A, Arathon E, et al. A randomized, doubleblind, multicenter trial of MK-991 vs amphotericin B in the treatment of Candida esophagitis in adults [abstract 15]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Program Addendum 1997 Sep 28–Oct 1; Toronto

    Google Scholar 

  3. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997 Nov; 41: 2333–8

    PubMed  CAS  Google Scholar 

  4. Bartizal K, Smith JG, Gill CJ, et al. Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis [abstract 159]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

    Google Scholar 

  5. Graybill JR, Najvar LK, Montalbo EM, et al. Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother 1998 Jan; 42: 151–3

    PubMed  CAS  Google Scholar 

  6. Connolly P, Durkin M, Kohler S, et al. Comparison of Merck’s pneumocandin L743,872 with amphotericin B for treatment of pulmonary histoplasmosis in a murine model [abstract 159]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

    Google Scholar 

  7. Powles MA, Anderson J, Liberator P, et al. Efficacy of semisynthetic pneumocandin analog L-743,872 against Pneumocystis carinii in murine models. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans

    Google Scholar 

  8. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998 Aug; 42: 1985–9

    PubMed  CAS  Google Scholar 

  9. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997 Nov; 41: 2326–32

    PubMed  CAS  Google Scholar 

  10. Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998 Apr; 30: 251–5

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caspofungin. Drugs R&D 1, 165–167 (1999). https://doi.org/10.2165/00126839-199901020-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901020-00011

Keywords

Search

Navigation